Suppr超能文献

一种用于快速生产蛋白质生物制品的无细胞表达和纯化工艺。

A cell-free expression and purification process for rapid production of protein biologics.

作者信息

Sullivan Challise J, Pendleton Erik D, Sasmor Henri H, Hicks William L, Farnum John B, Muto Machiko, Amendt Eric M, Schoborg Jennifer A, Martin Rey W, Clark Lauren G, Anderson Mark J, Choudhury Alaksh, Fior Raffaella, Lo Yu-Hwa, Griffey Richard H, Chappell Stephen A, Jewett Michael C, Mauro Vincent P, Dresios John

机构信息

CBRN Division, Leidos, Inc., San Diego, CA, USA.

Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA.

出版信息

Biotechnol J. 2016 Feb;11(2):238-48. doi: 10.1002/biot.201500214. Epub 2015 Dec 7.

Abstract

Cell-free protein synthesis has emerged as a powerful technology for rapid and efficient protein production. Cell-free methods are also amenable to automation and such systems have been extensively used for high-throughput protein production and screening; however, current fluidic systems are not adequate for manufacturing protein biopharmaceuticals. In this work, we report on the initial development of a fluidic process for rapid end-to-end production of recombinant protein biologics. This process incorporates a bioreactor module that can be used with eukaryotic or prokaryotic lysates that are programmed for combined transcription/translation of an engineered DNA template encoding for specific protein targets. Purification of the cell-free expressed product occurs through a series of protein separation modules that are configurable for process-specific isolation of different proteins. Using this approach, we demonstrate production of two bioactive human protein therapeutics, erythropoietin and granulocyte-macrophage colony-stimulating factor, in yeast and bacterial extracts, respectively, each within 24 hours. This process is flexible, scalable and amenable to automation for rapid production at the point-of-need of proteins with significant pharmaceutical, medical, or biotechnological value.

摘要

无细胞蛋白质合成已成为一种用于快速高效生产蛋白质的强大技术。无细胞方法也适合自动化,并且此类系统已广泛用于高通量蛋白质生产和筛选;然而,当前的流体系统并不适合生产蛋白质生物药物。在这项工作中,我们报告了一种用于重组蛋白质生物制品快速端到端生产的流体工艺的初步开发。该工艺包含一个生物反应器模块,该模块可与真核或原核裂解物一起使用,这些裂解物被编程用于对编码特定蛋白质靶标的工程化DNA模板进行联合转录/翻译。无细胞表达产物的纯化通过一系列蛋白质分离模块进行,这些模块可配置用于针对不同蛋白质的特定工艺分离。使用这种方法,我们分别在酵母和细菌提取物中展示了两种生物活性人蛋白质治疗剂促红细胞生成素和粒细胞-巨噬细胞集落刺激因子的生产,每种均在24小时内完成。该工艺灵活、可扩展且适合自动化,以便在需要时快速生产具有重大制药、医学或生物技术价值的蛋白质。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验